Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention that the president calls a turning ...

The global fight against HIV/AIDS is in peril amid wide-scale cuts to prevention programs, according to a United Nations ...

Yeztugo (lenacapavir) is more than 99.9 percent effective at protecting at-risk people from HIV — but for many, accessing the drug may be a challenge. Yeztugo (lenacapavir) is the first and only ...

ViiV's new awareness campaign educates consumers that there are different kinds of PrEP treatments, including long-lasting ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Example antibody-drug conjugate A recent experimental treatment may offer a new method to ...

The World Health Organization (WHO) praised the initiative, describing it as an important milestone in expanding access to ...

A very early study suggests flu antivirals might help reverse certain signs of accelerated aging in people with HIV. But more ...

Children living with HIV ‘not getting treatment needed’ as aid cuts hit services - A year after global HIV funding was ...